Advanced Proteome Therapeutics Corporation announced the appointment of Dr. Randal Chase to its executive leadership team to help shape the company's future and advance its technology and business objectives in the domain of antibody-based therapeutics. Effective February 6, 2017, Dr. Randal Chase, a member of the Board of Directors since June 2, 2015, will assume the role of Chief Executive Officer (CEO) and President, while Allen (Alexander) Krantz will step down as CEO/President and assume the newly created roles of Chief Scientific Officer (CSO) and Chief Operating Officer (COO). The leadership changes are intended to accelerate the growth of the company and capitalize on the business opportunities that have emerged from the company's new directions in antibody R&D.